Abstract: Embodiments described herein provide orthohepadnavirus capsid protein (Cp) heterodimers, bicistronic vectors encoding the heterodimers, and methods for producing the heterodimers. The heterodimers can be used to form mosaic virus-like particles. In certain embodiments, the heterodimers can form a hexamer, which in turn can be used to nucleate capsid formation, resulting in a Janus particle-like virus-like particle. The hexamer's can then be removed, leaving holey capsids. The capsids can be loaded with, for example, one or more polypeptides, small molecules, or a combination of polypeptides and small molecules. The holes of the holey capsids can be filled with another orthohepadnavirus heterodimer or a homodimer.

Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

Abstract: Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.

Abstract: Virus capsids protect the viral genome and play roles in its delivery and intracellular transport, making them an attractive target for antiviral therapeutics. The difficulty in targeting capsid assembly is to identify molecules that interfere with the weak protein-protein interactions that drive the reaction. We have developed an in vitro assay for capsid assembly that works on a range of viruses at biologically relevant protein concentrations to facilitate screening large libraries of chemicals for lead compounds.

Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

Abstract: Heteroaryldihydropyrimidine (HAP)-based fluorescent stains (compounds), as well as uses of such stains as diagnostic reagents, viral-tracking agents, and/or tools for drug discovery are described. The present invention relates to heteroaryldihydropyrimidine (HAP)-based fluorescent stains (compounds), as well as uses of such stains as diagnostic reagents, viral-tracking agents, and/or tools for drug discovery.

Abstract: This disclosure provides a novel strategy to cope with chronic virus infection by introducing a dominant negative viral structural protein to disturb effective virion production. The dominant negative structural protein mimics antiviral drugs through structural and biochemical interactions during virus assembly. An effective gene therapy model for chronic viral infected diseases is proposed in this disclosure, as represented by HBV Cpdominant1 to clear viral infection.

Abstract: Novel virus assembly effector compounds having a therapeutic effect against Hepatitis B viral infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed are pharmaceutical compositions including the disclosed compounds, methods of treatment of HBV infection, and a process to synthesize the disclosed compounds.

Abstract: Described herein are methods for identifying compounds useful for the treatment of infection by hepatitis B virus (HBV) and for identifying compounds useful for the same.

Abstract: In addition to containing and protecting the viral genome, the capsid (protein shell) of hepatitis B virus (HBV) plays critical roles in the viral life cycle including regulation of intracellular trafficking and nucleic acid metabolism. Substituted pyrimidine modulators of the assembly of the HBV capsid structure and methods for their use are described.

Abstract: Virus capsids protect the viral genome and play roles in its delivery and intracellular transport, making them an attractive target for antiviral therapeutics. The difficulty in targetting capsid assembly is to identify molecules that interfere with the weak protein-protein interactions that drive the reaction. We have developed an in vitro assay for capsid assembly that works on a range of viruses at biologically relevant protein concentrations to facilitate screening large libraries of chemicals for lead compounds.

Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

Abstract: In addition to containing and protecting the viral genome, the capsid (protein shell) of hepatitis B virus (HBV) plays critical roles in the viral life cycle including regulation of intracellular trafficking and nucleic acid metabolism. Substituted pyrimidine modulators of the assembly of the HBV capsid structure and methods for their use are described.

Abstract: Heteroaryldihydropyrimidine (HAP)-based fluorescent stains (compounds), as well as uses of such stains as diagnostic reagents, viral-tracking agents, and/or tools for drug discovery are described. The present invention relates to heteroaryldihydropyrimidine (HAP)-based fluorescent stains (compounds), as well as uses of such stains as diagnostic reagents, viral-tracking agents, and/or tools for drug discovery.

Abstract: Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.

Abstract: Described herein are methods for identifying compounds useful for the treatment of infection by hepatitis B virus (HBV).

Abstract: In addition to containing and protecting the viral genome, the capsid (protein shell) of hepatitis B virus (HBV) plays critical roles in the viral life cycle including regulation of intracellular trafficking and nucleic acid metabolism. Substituted pyrimidine modulators of the assembly of the HBV capsid structure and methods for their use are described.

Abstract: This disclosure provides a novel strategy to cope with chronic virus infection by introducing a dominant negative viral structural protein to disturb effective virion production. The dominant negative structural protein mimics antiviral drugs through structural and biochemical interactions during virus assembly. An effective gene therapy model for chronic viral infected diseases is proposed in this disclosure, as represented by HBV Cpdominant 1 to clear viral infection.